Study on invasive bacterial diseases and their epidemiology

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the epidemiology of invasive bacterial diseases caused by Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. It aims to improve pathogen identification through molecular diagnostic methods, which can detect bacteria even when they are not viable. By analyzing blood specimens from patients, the study seeks to characterize circulating strains and assess the impact of vaccination strategies. The findings will guide public health interventions and improve treatment and prevention strategies for these serious infections.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pediatric and adult patients diagnosed with pneumococcal, meningococcal, and hemophilus MBI

Exclusion Criteria:

* Other type of bacterial infections.

Where it's running

• Immunology Laboratory Meyer Children's Hospital IRCCS
  Florence, Italy Recruiting
• Ospedale di Adria
  Adria, Italy Not yet recruiting
• Ospedali riuniti di Ancona
  Ancona, Italy Not yet recruiting
• Ospedale di Andria
  Andria, Italy Not yet recruiting
• Ospedale Giovanni XXIII
  Bari, Italy Not yet recruiting
• Policlinico S.Orsola-Malpighi IRCCS
  Bologna, Italy Not yet recruiting

Study contacts

• Study coordinator: Chiara Azzari, MD
• Email: chiara.azzari@meyer.it
• Phone: 00390555662542

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preparing for maternal vaccines against Group B Streptococcus in Africa

  This study is trying to set up better ways to track pregnancy and baby health in East Africa to prepare for future vaccines against Group B Streptococcus, which can be dangerous for newborns.

  Recruiting at 10 sites Barcelona Institute for Global Health · Mariakani, Coast and 9 other locations · NCT06833957

• Autoimmune podocytopathy and anti-nephrin antibodies

  This study tests whether children and adults with nephrotic syndrome have anti-nephrin autoantibodies and whether those antibodies relate to relapses and treatment response.

  Recruiting Meyer Children's Hospital IRCCS · Rochester, Minnesota and 13 other locations · NCT07516964

• Pediatric leishmaniasis in Italy: clinical and treatment patterns

  This project will collect medical information to see how leishmaniasis presents and is treated in children under 18 in Italy.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Tuscany · NCT07504757

• Infliximab level monitoring in children with inflammatory bowel disease

  This project will test whether measuring infliximab levels in saliva and leftover blood during the first infusions helps monitor and personalize treatment for children and teens (ages 3–18) with Crohn's disease or ulcerative colitis.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Italy · NCT07470502

• Camptodactyly–Arthropathy–Coxa Vara–Pericarditis (CACP) syndrome patient registry and genetic review

  This registry collects clinical and genetic information to better understand CACP syndrome in children with confirmed PRG4 mutations.

  Recruiting at 3 sites Meyer Children's Hospital IRCCS · Bari and 9 other locations · NCT07468461

• ECD-Score: tracking disease features and outcomes in Erdheim-Chester disease

  This observational project will collect clinical, molecular, and treatment data from people with Erdheim‑Chester disease to try to create an 'ECD‑Score' that tracks disease activity and outcomes.

  Recruiting Meyer Children's Hospital IRCCS · Bethesda, Maryland and 6 other locations · NCT07454343

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.